OXFORD, England--(BUSINESS WIRE)--ProImmune Ltd., a leading provider of services for immune monitoring, antigen discovery and immunogenicity risk assessment, announced today that it has been accepted into the UK GLP (Good Laboratory Practice) compliance monitoring program by the MHRA (Medicines & Healthcare products Regulatory Agency) formally confirming ProImmune’s compliance with GLP. The accreditation will enable pharmaceutical and biotech companies worldwide to seamlessly incorporate ProImmune’s GLP, as well as GCP (Good Clinical Practice), compliant services, such as cell-mediated immunity assays, into their preclinical and clinical development programs, with the confidence that the data will fully meet the different international regulatory submission requirements.
